Get the Stockscreener App
277.35
2.29%
6.22
After Hours:
277.00
-0.35
-0.13%
Penumbra Inc stock is traded at $277.35, with a volume of 361.86K.
It is up +2.29% in the last 24 hours and down -2.83% over the past month.
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
See More
Previous Close:
$271.13
Open:
$266.93
24h Volume:
361.86K
Relative Volume:
0.81
Market Cap:
$10.44B
Revenue:
$1.16B
Net Income/Loss:
$34.55M
P/E Ratio:
322.50
EPS:
0.86
Net Cash Flow:
$134.18M
1W Performance:
+0.80%
1M Performance:
-2.83%
6M Performance:
+43.69%
1Y Performance:
+31.13%
1-Day Range:
$265.76
$279.79
1-Week Range:
$258.95
$279.79
52-Week Range:
$148.00
$310.00
Penumbra Inc Stock (PEN) Company Profile
Name
Penumbra Inc
Sector
Industry
Phone
(510) 995-2486
Address
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
277.35 | 10.44B | 1.16B | 34.55M | 134.18M | 0.86 |
|
ABT
Abbott Laboratories
|
131.93 | 225.32B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
100.05 | 149.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
377.46 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
88.86 | 113.49B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.05 | 42.10B | 5.72B | 4.17B | 259.90M | 6.97 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-14-25 | Initiated | BofA Securities | Buy |
| Jan-21-25 | Initiated | UBS | Buy |
| Dec-17-24 | Initiated | Oppenheimer | Outperform |
| Dec-11-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-18-24 | Initiated | Stifel | Buy |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-31-24 | Downgrade | Citigroup | Buy → Neutral |
| Jul-31-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-23-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-06-23 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Mar-29-23 | Downgrade | Needham | Buy → Hold |
| Jan-30-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Oct-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Sep-09-22 | Upgrade | Needham | Hold → Buy |
| Jul-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Apr-19-22 | Initiated | Deutsche Bank | Buy |
| Mar-08-22 | Initiated | Needham | Hold |
| Sep-16-21 | Initiated | Truist | Buy |
| Jun-04-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-07-20 | Resumed | Canaccord Genuity | Buy |
| Sep-29-20 | Initiated | BTIG Research | Buy |
| Sep-08-20 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| May-30-19 | Upgrade | JP Morgan | Neutral → Overweight |
| May-21-19 | Initiated | William Blair | Outperform |
| Oct-29-18 | Resumed | BofA/Merrill | Buy |
| Oct-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Feb-21-18 | Initiated | William Blair | Outperform |
| Jan-02-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-30-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-13-15 | Initiated | Wells Fargo | Outperform |
View All
Penumbra Inc Stock (PEN) Latest News
Breakthrough Clinical Data: Penumbra's CAVT Slashes Hospital Stays by 46%, Achieves 99% Success Rate - Stock Titan
Meiji Yasuda Asset Management Co Ltd. Buys New Position in Penumbra, Inc. (NYSE:PEN) - MarketBeat
ROSEN, A LEADING LAW FIRM, Encourages Penumbra, Inc. Investors to Secure Counsel Before Important March 16 DeadlinePEN - PR Newswire
Penumbra Insider Sold Shares Worth $3,405,253, According to a Recent SEC Filing - MarketScreener
Penumbra director Arani sells $3.41 million in stock - Investing.com India
Thrombectomy Devices Market Surge: Key Players & Future Outlook - openPR.com
New Thrombectomy Product Launches Support PEN Stock Amid Macro Issues - MSN
Penumbra CEO Adam Elsesser sells $4.59 million in stock By Investing.com - Investing.com Australia
Penumbra CEO Adam Elsesser sells $4.59 million in stock - Investing.com
Do Its Financials Have Any Role To Play In Driving Penumbra, Inc.'s (NYSE:PEN) Stock Up Recently? - Yahoo Finance
Has Penumbra, Inc.'s (NYSE:PEN) Impressive Stock Performance Got Anything to Do With Its Fundamentals? - simplywall.st
Penumbra (PEN) Down 8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Peering Into Penumbra's Recent Short Interest - Benzinga
B of A Securities Initiates Coverage of Penumbra (BMV:PEN) with Buy Recommendation - Nasdaq
ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Reminds Penumbra, Inc. Investors of Important Deadline in Securities Class Action – PEN - Business Wire
Penumbra Inc (PEN) Trading 4.6% Higher on Mar 17 - GuruFocus.com
Penumbra Inc (PEN) Shares Up 4.6% on Mar 15 - GuruFocus.com
Penumbra launched at BofA with Buy on a broad rollout of Flash 2.0 - MSN
What Analysts Are Saying About Penumbra Stock - Benzinga
Penumbra stock launched at BofA with Buy (PEN:NYSE) - Seeking Alpha
B of A Securities Initiates Coverage of Penumbra (PEN) with Buy Recommendation - Nasdaq
Penumbra initiated with a Buy at BofA - TipRanks
Penumbra, Inc. (NYSE:PEN) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
Penumbra, Inc. (NYSE:PEN) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Penumbra Off And Running On Renewed Enthusiasm For Mechanical Thrombectomy - Seeking Alpha
Adam Elsesser Sells 61,600 Shares of Penumbra, Inc. (NYSE:PEN) Stock - Defense World
Johanna Roberts Sells 600 Shares of Penumbra, Inc. (NYSE:PEN) Stock - MarketBeat
Penumbra CEO Adam Elsesser sells $17.47 million in stock By Investing.com - Investing.com Canada
Penumbra CEO Adam Elsesser sells $17.47 million in stock - Investing.com
Penumbra director O’Rourke sells $14,274 in stock By Investing.com - Investing.com South Africa
Penumbra director Arani sells $3.45 million in stock By Investing.com - Investing.com South Africa
Penumbra’s Growth Potential Balanced by Market Uncertainties: A Hold Recommendation - TipRanks
Insider Sell: Bridget O'Rourke Sells Shares of Penumbra Inc (PEN) - GuruFocus
Penumbra, Inc. to Host Earnings Call - ACCESS Newswire
Insider Sell: Arani Bose Sells 12,000 Shares of Penumbra Inc (PE - GuruFocus.com
Penumbra director O’Rourke sells $14,274 in stock - Investing.com India
Penumbra EVP Johanna Roberts sells shares worth $172,458 - Investing.com India
Penumbra EVP Johanna Roberts sells shares worth $172,458 By Investing.com - Investing.com South Africa
Penumbra’s chief accounting officer sells shares worth over $2.2 million - Investing.com
Penumbra CFO Maggie Yuen sells $571,994 in stock - Investing.com
Penumbra director Arani sells $3.45 million in stock - Investing.com
Penumbra Announces Board Transition with Kassing’s Retirement - TipRanks
Aspiration-first approaches gather further traction thanks to ‘game-changing’ thrombectomy technologies - NeuroNews International
Penumbra Inc.: Will Its Market Penetration & Access Initiatives Help Capture The Thrombectomy Market? - Smartkarma
Penumbra Inc Stock (PEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
1.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):